Genmab uses ActivityBase XE to analyze results from its discovery activities, accelerating research into cancer, inflammatory conditions and infectious diseases.
Using unique antibody technology to target specific antigens involved in the pathology of disease, Genmab needed a solution to capture, validate and visualize screening data for monoclonal antibody-based products for the treatment of cancer, infectious diseases, rheumatoid arthritis and other inflammatory conditions.
Flexible data management was required to manage plate-based serum, and primary and secondary screening assays, to test antibodies for their specificity and functional characteristics.
Scientists needed to be able to compile graphical information and perform trend analysis on their data, with the aim to find a disease target that can be reproduced in large quantities as needed.
Genmab has implemented ActivityBase XE to help scientists detect subjects that are producing antibodies with the desired characteristics.
The solution’s trend analysis and visualization capabilities ensure that scientists can identify patterns of behavior within and across plates, determine the quality of the screen and select hits for the next screen.
ActivityBase XE uses assay results to determine the IC50/EC50 values for samples. The solution’s curve fitting functionality ensures analysis and reporting of data is more efficient and less error prone
Data is transparent across screens and can be accessed and retrieved at any stage for reference and further analysis.
With reliable and repeatable data capture, process and analysis, ActivityBase XE speeds up results generation and significantly improves data accuracy, quality and workflow efficiency.
All screening data is captured and stored in one accessible location, which provides context around the hybridoma discovery departments screening results, accelerating research into therapeutics with great efficacy and tolerability.
IDBS’ solution can accommodate a wide range of screening methodologies, offering Genmab the flexibility it needs to meet its hybridoma discovery data requirements